Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction

R. K. Wali, V. Mohanlal, E. Ramos, S. Blahut, C. Drachenberg, J. Papadimitriou, M. Dinits, A. Joshi, B. Philosophe, C. Foster, C. Cangro, J. Nogueira, M. Cooper, S. T. Bartlett, M. R. Weir

Research output: Contribution to journalArticlepeer-review

Abstract

Mammalian Target-of-Rapamycin inhibitors (mTOR inhibitors) can be used to replace the calcineurin inhibitors (CNIs) to prevent progression in chronic kidney disease (CKD) following organ transplantation. Discontinuation of tacrolimus in 136 recipients of kidney transplants with progressive renal dysfunction significantly decreased the rate of loss of estimated glomerular filtration rate (eGFR, mL/min/1.73 m2) (pre-intervention vs. post-intervention slopes, -0.013 vs. -0.002, p < 0.0001). Discontinuation of tacrolimus was associated with a sustained and significant improvement in graft function (pre-eGFR vs. post-eGFR; 26.0 ± 1.1 vs. 47.4 ± 2.1, p < 0.0001) in 74% of patients. This intervention was ineffective if the mean and (median) values of creatinine (mg/dL) and eGFR were 3.8 ± 0.2 (3.4) and 18.4 ± 1.9 (22.4), respectively, at the time of conversion therapy. During the follow-up (range, 1.5-34.6, months), a total of 13 patients had their first acute rejection following the conversion therapy, an annual incidence of less than 10% and none of these episodes resulted in graft loss. The salutary effects of sirolimus therapy following discontinuation of tacrolimus in patients with moderate to severe graft dysfunction due to allograft nephropathy even in high-risk patients improves kidney function and prevents acute rejection.

Original languageEnglish (US)
Pages (from-to)1572-1583
Number of pages12
JournalAmerican Journal of Transplantation
Volume7
Issue number6
DOIs
StatePublished - Jun 2007
Externally publishedYes

Keywords

  • Acute rejection
  • Calcineurin inhibitors
  • Chronic allograft nephropathy
  • Chronic kidney disease
  • Kidney transplants
  • Target-of-Rapamycin inhibitors (mTOR inhibitors)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction'. Together they form a unique fingerprint.

Cite this